Home > Investor Relations
Achillion is focused on solutions for the most challenging problems in infectious disease.
The investor pages that follow are your resource for financial information about Achillion Pharmaceuticals. In this section you will find information about our current and historical share price, analyst coverage, SEC filings, an electronic version of our annual report and frequently asked questions as well as forms to request additional information.
Aug 19, 2014
Aug 15, 2014
Achillion Achieves 100 Percent Sustained Virologic Response Rate (SVR4) From an Eight Week Phase 2 Trial Evaluating a Ribavirin-Free Regimen of ACH-3102 and Sofosbuvir for Genotype 1 HCV ("Proxy Study")